Evidence map›Paper›PMID 41523907›Full record

ArticleTherapeutic advances in medical oncology2026

Cancer-derived inflammation is associated with bevacizumab resistance and inferior clinical outcomes in patients with metastatic colorectal cancer.

Ya-Nan Li, Yang Wu, Feng-Wen Deng, Ying Lu, Guo-Bin Song, Lin Xiang, Tian Peng, Xue-Xin Cheng, Hou-Qun Ying

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in medical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ya-Nan LiJiangxi Province Key Laboratory of Immunology and Inflammation, Jiangxi Provincial Clinical Research Center for Laboratory Medicine, Department of Clinical Laboratory, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.ORCID https://orcid.org/0009-0009-1421-4863
Yang WuJiangxi Province Key Laboratory of Immunology and Inflammation, Jiangxi Provincial Clinical Research Center for Laboratory Medicine, Department of Clinical Laboratory, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.ORCID https://orcid.org/0000-0002-3215-0789
Feng-Wen DengDaye People's Hospital, Affiliated Hospital of Hubei Polytechnic University, Huangshi, Hubei, China.ORCID https://orcid.org/0009-0007-4727-1755
Ying LuJiangxi Province Key Laboratory of Immunology and Inflammation, Jiangxi Provincial Clinical Research Center for Laboratory Medicine, Department of Clinical Laboratory, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.ORCID https://orcid.org/0000-0002-3032-0318
Guo-Bin SongJiangxi Province Key Laboratory of Immunology and Inflammation, Jiangxi Provincial Clinical Research Center for Laboratory Medicine, Department of Clinical Laboratory, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.ORCID https://orcid.org/0000-0003-1046-6560
Lin XiangJiangxi Province Key Laboratory of Immunology and Inflammation, Jiangxi Provincial Clinical Research Center for Laboratory Medicine, Department of Clinical Laboratory, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.ORCID https://orcid.org/0009-0002-9306-6406
Tian PengJiangxi Province Key Laboratory of Immunology and Inflammation, Jiangxi Provincial Clinical Research Center for Laboratory Medicine, Department of Clinical Laboratory, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.ORCID https://orcid.org/0009-0002-9570-6374
Xue-Xin ChengDepartment of Clinical Laboratory, Immunity and Inflammation Key Laboratory of Jiangxi Province, The Second Affiliated Hospital of Nanchang University, No. 1 Minde Road, Nanchang, Jiangxi 330006, China.ORCID https://orcid.org/0000-0003-2241-2535
Hou-Qun YingJiangxi Province Key Laboratory of Immunology and Inflammation, Jiangxi Provincial Clinical Research Center for Laboratory Medicine, Department of Clinical Laboratory, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 1 Minde Road, Nanchang, Jiangxi 330006, China.ORCID https://orcid.org/0000-0003-3858-4761

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cancer-derived inflammation has been shown to attenuate the efficacy of chemotherapy (CT) in colorectal cancer. However, its role in clinical response to bevacizumab (Bev) remains unclear in patients with metastatic colorectal cancer (mCRC). Objectives: To investigate the clinical significance of the fibrinogen-to-prealbumin ratio (FPR) as a biomarker in mCRC patients receiving first-line Bev plus CT (Bev/CT). Design: A retrospective, single-center, observational study. Methods: Patients treated with first-line Bev/CT were enrolled across discovery ( Results: Elevated pretreatment FPR was significantly associated with increased tumor burden. FPR-H patients exhibited an unfavorable DCR compared to the FPR-L patients in the overall Bev/CT-treated population (adjusted odds ratio (OR) = 2.18, 95% confidence interval (CI) = 1.32-3.61, Conclusion: Cancer-derived inflammation appears to play a crucial role in mediating both intrinsic and acquired resistance to Bev. The FPR emerges as a robust, independent biomarker for predicting response to Bev, monitoring disease progression, and informing personalized therapeutic decision-making in patients with mCRC.

Indexed as

bevacizumabcolorectal cancerfibrinogen-to-prealbumin ratioinflammationtherapeutic resistance

Identifiers

PMID41523907
PMCPMC12779915

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.